Please assess the completion status of the following clinical trial:

Trial Title: Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed diagnosis of invasive breast cancer, previously untreated~* Patients must be postmenopausal~* Candidates for mastectomy or breast-conserving surgery~* Primary tumor of above 2 cm diameter, measured by imaging~* Clinical Stage M0~* WHO performance status ≤1~* Adequate bone marrow, liver, and renal function~Exclusion Criteria:~* Multicentric invasive tumors~* Bilateral or inflammatory breast cancer~* Receiving concomitant anti-cancer treatments such as chemotherapy~* Patients with an uncontrolled infection~* Patients with other concurrent severe and/or uncontrolled medical disease~Additional protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 + letrozole 2.5mg (Type: EXPERIMENTAL): None
- Letrozole 2.5mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).